Oxford BioMedica says licensing talks heating up

Oxford BioMedica says its in talks with four other companies interested in collaborating on the development of its cancer drug TroVax, its lead therapy. And they added that one major pharma company has already completed due diligence on the drug, which is starting Phase III. A spokesman for the company said that their goal was to bring all four companies interested in TroVax up to the same level, which certainly sounds as if they'd like to get the serious bidders to the table as swiftly as possible. Oxford BioMedica also offered up more positive data from a Phase II trial of TroVax.

- here's a report on the licensing talks from the Oxford Mail
- and here's more on the new trial data

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.